Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ginger, valerian, comfrey "informational" monographs published by USP.

This article was originally published in The Tan Sheet

Executive Summary

GINGER FOR NAUSEA, VOMITING REQUIRES FURTHER STUDY before the plant can be recommended for use in humans, the U.S. Pharmacopeia states in an "informational" monograph released in January. Upon considering available literature on ginger, USP advisory panels suggest future research, "including at least one adequate and well-controlled clinical trial," be conducted to examine the botanical's reported uses for the treatment and prevention of nausea and vomiting related to motion sickness. The monograph is published in the monthly update to the USP DI compendium of drug, nutritional and therapeutic information.
Advertisement

Related Content

USP Negative Ephedra Monograph To Follow FDA Final Action
USP Negative Ephedra Monograph To Follow FDA Final Action
USP Negative Ephedra Monograph To Follow FDA Final Action

Topics

Advertisement
UsernamePublicRestriction

Register

PS088049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel